Context: A four marker haplotype in the 5' region of the Fc receptor-like 3 gene (markers FCRL3_3 to FCRL3_6) has recently been identified as contributing to rheumatoid arthritis susceptibility in the Japanese population. The promoter FCRL3_3*C allele also showed significant association with autoimmune thyroid disease and systemic lupus erythematosus.
Introduction
Autoimmune endocrinopathies, together with immune-mediated rheumatological disorders contribute the major burden of disease caused by autoimmunity in the population, with around 5% of women in developed societies being affected by such conditions. All the common autoimmune conditions have a complex genetic basis, with autoimmune endocrinopathies and rheumatoid arthritis (RA) commonly occurring in the same individual and clustering within families [1] . Graves' disease (GD), RA, and type 1 diabetes (T1D) are frequent disorders (prevalence 0.4-1%), and each has a !s (ratio of risk to sibling vs unrelated background population) of between 7 and 15, suggesting a significant genetic component to susceptibility. In contrast, autoimmune Addison's disease (AAD) is a much rarer condition with a prevalence of about 1 per 10,000 people in the UK [2] but a risk to first-degree relatives of about 2%, suggesting a more marked genetic influence on disease susceptibility. Whole-genome linkage studies have shown clustering of susceptibility loci for many of these different disorders and several loci consistently appear to contribute to multiple forms of autoimmunity across diverse populations. Examples of such loci include the major histocompatibility complex (MHC) [3, 4] , the cytotoxic T lymphocyte antigen-4 gene (CTLA4) [5] [6] [7] [8] [9] [10] and the protein tyrosine phosphatase non-receptor type 22 gene (PTPN22) [11] [12] [13] . A second class of autoimmunity susceptibility locus is represented by the disease-specific loci, such as the insulin gene (INS, IDDM2) [14] , or the thyrotropin receptor [15, 16] whose contribution is unique to the relevant target tissue or specific antigen of the autoimmune response. A final class of loci are those where replicable disease associations are found in some populations studied, but for which there appears to be little or no contribution to disease in well-powered studies of other populations. For example the PADI4 gene is associated with RA in the Japanese population [17] [18] [19] ; odds ratio 2.15) was found in individuals who were homozygote carriers of a particular promoter allele, FCRL3_3*C, at position -169 relative to the FCRL3 transcription start site. This allele (FCRL3_3*C ) was also found to be associated in Japanese cohorts with autoimmune thyroid disease (p=1.7x10 -5 ; odds ratio 1.74) and systemic lupus erythematosus (p=0.0017; odds ratio 1.49). This same allele was also found to produce higher promoter activity in a reporter gene assay and to be more avidly bound by NF"B in gel-shift studies, suggesting a direct functional role [24] . FCRL3 is an orphan cell-surface receptor with homology to the Fc immunoreceptors, and is expressed predominantly in B-lymphocytes in lymph node germinal centres. In this study we have analysed the same 4 marker FCRL3 SNP haplotype and 3 additional exonic SNP markers in four cohorts of white Caucasians with autoimmune disorders including GD, AAD, RA and T1D.
Materials and Methods

Subjects
The GD (n=625) and AAD (n=105) probands were recruited through endocrine and combined physician-ophthalmologist thyroid associated ophthalmopathy clinics at the Newcastle upon Tyne Hospitals Trust and surrounding district hospitals. A further cohort of 95 AAD probands were recruited via the UK Addison's disease self-help group. The diagnostic criteria of these cohorts have been published previously [28, 29] . Of the GD probands 78% were female, 38% had significant thyroid associated opthalmopathy (NOSPECS class 3 or worse) and 55% were AAD probands also had an affected first degree relative with AAD (two siblings, two offspring).
None of the AAD subjects had autoimmune hypoparathyroidism or candidiasis (subjects with type 1 polyendocrinopathy were excluded from the cohort) [28] . UK controls (n=490; 66.3% females, 33.7% males) also recruited from the local population had no clinical features or family history of autoimmune disease. The RA (n=769) cases were recruited from rheumatology clinics throughout New Zealand and details of their clinical characterisation, and of the NZ control cohort (n=563) have previously been published [13] . The T1D cohort comprised 279 subjects with hyperglycaemia and ketosis who were commenced on insulin therapy at diagnosis, recruited from endocrinology clinics throughout New Zealand. They had an average age of onset of 12.5 years.
SNP genotyping
The SNPs within the 4-marker haplotype described by Kochi et al (2005) [24] were genotyped either by PCR and restriction enzyme digest (RFLP) (UK cohort SNPs FCRL3_3, 3_4; NZ cohort 
Statistical analysis
The case-control association studies were analysed using # 2 tests on 2x2 and 2x3 contingency tables for allele and genotype frequencies, respectively. Haplotype frequencies were estimated, and linkage disequilibrium (r 2 ) measures were calculated using the SHEsis package [30] . Odds ratios and confidence intervals were calculated using Woolf's method. No significant deviation from Hardy Weinberg equilibrium was observed for any of the SNPs in this study (all p>0.05).
The overall genotype call rate was 98.2% (range 91.6-100%), and the accuracy was >99%
according to duplicate genotyping of 7-10% of samples. We estimate that our studies of GD and RA had more than 80% power to detect an effect ($=0.001) of the same magnitude (allelic odds ratio of 1.4) as that found in the Japanese GD cohorts [24], using our control allele frequencies and a binomial model. The power of our studies of AAD and T1D were >80% and >90%, respectively, assuming an allelic odds ratio of 1.4 ($=0.05). P values were Bonferroni corrected for multiple tests assuming that the 7 SNP markers carried information for 4 independent linkage groups, and that each of the 4 disease states were independent.
Results
We found significant linkage disequilibrium between markers at the 5' end of FCRL3, but lesser association between the other 3' alleles, with pairwise r 2 values based on the UK control population as follows: with a p value of 0.001 using a global test of the 6 common haplotypes found in the AAD patients (Table 2 ). There were no significant haplotype associations with disease in either of the GD, RA or T1D cohorts (Table 2 ). There was no significant heterogeneity in the allelic associations in the various cohorts when divided by diagnostic subgroups (supplementary table 2 ).
Discussion
The association of multiple autoimmune disorders in the Japanese population with alleles of FCRL3 by Kochi and colleagues [24] suggested that this locus may affect susceptibility to different autoimmune diseases across many populations, in a similar way to the action of alleles -8 - at CTLA4 [5] [6] [7] [8] [9] [10] . The association of the FCRL3_3*C allele with susceptibility to autoimmune conditions found in this initial study has recently been replicated in a further cohort of Japanese subjects with rheumatoid arthritis (n=752) [31] . Furthermore, a study of a white UK population showed a weak effect in Graves' disease, with FCRL3 markers having nominal association (FCRL3_3*C, p=0.024, OR 1.17) [32] . However, similar investigation of several additional large cohorts of Caucasian subjects with T1D and RA have failed to replicate the FCRL3_3 association [33] [34] [35] [36] . In contrast to these studies, our investigation found that the FCRL3_3*C allele was associated with protection from autoimmune Addison's disease; an observation that largely refutes the hypothesis that this allele is the disease-causing polymorphism for autoimmunity at this locus, at least not in Caucasians. In addition, our extended genotyping points to the exon 3 cSNP (D28N) as also being tightly associated with FCRL3_3 (r 2 > 0.9; Figure 1 ) and this marker certainly warrants examination in Japanese and other autoimmune disease cohorts. While our analyses of rheumatoid arthritis and Graves' disease were well-powered to detect an effect of similar magnitude to that found in the Japanese cohorts, only marginal evidence for association was found in these conditions; this being found at the 3' FCRL3 SNPs (designated FCRL3_9 and FCRL3_8, respectively), which are not in the haplotype block containing the promoter and exon 3 markers ( Figure 1 ). Table 1 . Genotype and allele data for each of the seven FCRL3 single nucleotide polymorphisms (SNPs) in each population studied, together with case control analysis of the alleles and genotypes in each disease group in comparison to the relevant controls. 
Global p value
0.001 *The p value for the association of the TGGGAAA haplotype in AAD is 1.1x10 -4 , when corrected for the 6 haplotypes observed. † no significant association of any of the FCRL3 haplotypes in these patient cohorts in comparison to the relevant controls. AAD, autoimmune Addison's disease; GD, Graves' disease; NZ, New Zealand; RA, rheumatoid arthritis; T1D, type 1 diabetes 
